Hemophilia in Iran

References

• Kulkarni R, Soucie JM, editors. Pediatric hemophilia: a review. Semin Thromb Hemost. 2011; 37(7):737–44.
   Google Scholar
• Carcao MD, editor. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost. 2012; 38(7):727–34.
   Google Scholar
• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003; 9(4):418–35.
   Google Scholar
• Yacoub A. Diagnosis, successful hemostasis and peri-operative management of an elderly man with undiagnosed hemophilia B undergoing a complex neurosurgery. Blood. 2013;122(21):4789–90.
   Web of Science ®Google Scholar
• Valleix S, Vinciguerra C, Lavergne J-M, Leuer M, Delpech M, Negrier C. Skewed X-chromosome inactivation in monochorionicdiamniotic twin sisters results in severe and mild hemophilia A. Blood. 2002;100(8):3034–6. doi: 10.1182/blood-2002-01-0277
   PubMed Web of Science ®Google Scholar
• Forsyth A, Witkop M, Guelcher C, Lambing A, Cooper DL. Is bleeding in hemophilia really spontaneous or activity related: analysis of US patient/caregiver data from the Hemophilia Experiences, Results and Opportunities (HERO) study. Blood. 2013;122(21):2364–3264.
   Google Scholar
• Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013; 4(1):59–72.
   PubMedGoogle Scholar
• Kenet G, Bidlingmaier C, Bogdanova N, Ettingshausen CE, Goldenberg N, Gutsche S, et al. Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A-an Israeli-German multicenter database study. Thromb Res. 2014;133(4):544–9. doi: 10.1016/j.thromres.2014.01.005
   PubMed Web of Science ®Google Scholar
• Astermark J. Genetic and environmental risk factors for factor VIII inhibitor development. In: C. A. Lee, E. E. Berntorp and W. K. Hoots., editor. Textbook of hemophilia. Vol. 3; 2014. p. 48–52.
   Google Scholar
• Report on the WFH Global Survey. Compiled and produced by the World Federation of Hemophilia. 2014.
   Google Scholar
• Mehdizadeh M, Kardoost M, Zamani G, Baghaeepour M, Sadeghian K, Pourhoseingholi M. Occurrence of haemophilia in Iran. Haemophilia. 2009;15(1):348–51. doi: 10.1111/j.1365-2516.2008.01874.x
   PubMed Web of Science ®Google Scholar
• Ziaei J, Dolatkhah R, Dastgiri S, Mohammadpourasl A, Asvadi I, Mahmoudpour A, et al. Inherited coagulation disorders in the northwestern region of Iran. Haemophilia. 2005;11(4):424–6. doi: 10.1111/j.1365-2516.2005.01118.x
   PubMed Web of Science ®Google Scholar
• Mansouritorghabeh H, Manavifar L, Banihashem A, Modaresi A, Shirdel A, Shahroudian M, et al. An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran. Blood Transfus. 2013;11(2):233.
   PubMed Web of Science ®Google Scholar
• Karimi M, Haghpanah S, Amirhakimi A, Afrasiabi A, Dehbozorgian J, Nasirabady S. Spectrum of inherited bleeding disorders in southern Iran, before and after the establishment of comprehensive coagulation laboratory. Blood Coagul Fibrinolysis. 2009;20(8):642–5. doi: 10.1097/MBC.0b013e32832f4371
   PubMed Web of Science ®Google Scholar
• Rezaei N, Aliasgharpoor M. Prevalence of factor VIII inhibitor in patients with hemophilia A in Sanandaj. J Kermanshah Univ Med Sci. 2011;15(2):127–31.
   Google Scholar
• Sharifian R, Hosseini M, Safai R, Gh T, Ehsani A, Lak M, et al. Prevalence of inhibitors in a population of 1280 hemophilia a patients in Iran. Acta Medica Iranica. 2003;41(1):66–8.
   Google Scholar
• Haghpanah S, Bazrafshan A, Silavizadeh S, Dehghani J, Afrasiabi A, Karimi M. Evaluation of thrombin generation assay in patients with hemophilia. Clin Appl Thromb Hemost. 2014;6(4):1–5.
   Google Scholar
• Mansouritorghabeh H. Clinical and laboratory approaches to hemophilia A. Iran J Med Sci. 2015;40(3):194.
   PubMed Web of Science ®Google Scholar
• Modaresi A, Torghabeh HM, Pourfathollah A, Shooshtari MM, Yazdi ZR. Pattern of factor VIII inhibitors in patients with hemophilia A in the north east of Iran. Hematology. 2006;11(3):215–7. doi: 10.1080/10245330600667526
   PubMed Web of Science ®Google Scholar
• Ravanbod S, Rassoulzadegan M, Rastegar-Lari G, Jazebi M, Enayat S, Ala F. Identification of 123 previously unreported mutations in the F8 gene of Iranian patients with haemophilia A. Haemophilia. 2012;18(3):e340–e6. doi: 10.1111/j.1365-2516.2011.02708.x
   PubMed Web of Science ®Google Scholar
• Boekhorst J, Lari G, D'oiron R, Costa J, Novakova I, Ala F, et al. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia. 2008;14(4):729–35. doi: 10.1111/j.1365-2516.2008.01694.x
   PubMed Web of Science ®Google Scholar
• Haghpanah S, Sahraiian M, Afrasiabi A, Enayati S, Peyvandi F, Karimi M. The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran. Haemophilia. 2011;17(5):820–1.
   PubMed Web of Science ®Google Scholar
• Enayat M, Arjang Z, Lavergne J, Ala F. Identification of intron 1 and 22 inversion mutations in the factor VIII gene of 124 Iranian families with severe haemophilia A. Haemophilia. 2004;10(4):410–1. doi: 10.1111/j.1365-2516.2004.00920.x
   PubMed Web of Science ®Google Scholar
• Rafati M, Ravanbod S, Hoseini A, Rassoulzadegan M, Jazebi M, Enayat M, et al. Identification of ten large deletions and one duplication in the F8 gene of eleven unrelated Iranian severe haemophilia A families using the multiplex ligation-dependent probe amplification technique. Haemophilia. 2011;17(4):705–7. doi: 10.1111/j.1365-2516.2010.02476.x
   PubMed Web of Science ®Google Scholar
• Roozafzay N, Kokabee L, Zeinali S, Karimipoor M. Analysis of Intron 1 Inversion at F8 gene in severe hemophilia A patients by inverse shifting-PCR referred from Isfahan Seyedolshohada Hospital. J Ardabil Univ Med Sci. 2013;13(1):93–101.
   Google Scholar
• Onsori H, Feizi MAH, Feizi AAH. A novel missense mutation, E1623G, in the human factor VIII gene associated with moderate haemophilia A. Iran Red Crescent Med J. 2014;16(1):e672–7. doi: 10.5812/ircmj.6727
   Web of Science ®Google Scholar
• Onsori H, Hosseinpour MA, Montaser-Kouhsari S, Asgharzadeh M, Hosseinpour AA. Identification of a novel missense mutation in exon 4 of the human factor VIII gene associated with sever hemophilia A patient. Pak J Biol Sci. 2007;10(23):4299–302. doi: 10.3923/pjbs.2007.4299.4302
   PubMedGoogle Scholar
• Zadeh-Vakili A, Eshghi P, Lari GR. Efficiency of BclI restriction fragment length polymorphism for detection of hemophilia A carriers in Sistan and Baluchestan Province, Southeast of Iran. Iran J Med Sci. 2015;33(1):33–6.
   Google Scholar
• Moharrami T, Derakhshan SM, Pourfeizi AAH, Khaniani MS. Detection of hemophilia A carriers in Azeri Turkish population of Iran usefulness of HindIII and BclI markers. Clin Appl Thromb Hemost. 2014;6(4):1–5.
   Google Scholar
• Karimipour M, Zeinali S, Graham Tuddenham E, Nafissi N, Lak M, Green P. Molecular characterization of the factor IX gene in 28 Iranian hemophilia B patients. Iran J Blood Cancer. 2009;1(2):43–7.
   Google Scholar
• Karimipoor M, Zeinali S, Nafissi N, Tuddenham EG, Lak M, Safaee R. Identification of factor IX mutations in Iranian haemophilia B patients by SSCP and sequencing. Thromb Res. 2007;120(1):135–9. doi: 10.1016/j.thromres.2006.07.011
   PubMed Web of Science ®Google Scholar
• Kamali DE, Karimipour M, Samiei S, Kokabee L, Zinali S, Nafissi N, et al. Mutation analysis of coagulation factor IX gene in Esfahanian hemophilia B patients by SSCP and sequencing. Sci J Blood Transfus Organ. 2007;4(3):299–308.
   Google Scholar
• Karimi NK, Koukabi L, Badiei Z, Shahabi M, Banihashem S, Zeynali S, et al. Molecular analysis of coagulation factor IX gene in hemophilia B patients of KhorasanRazavi Province. Sci J Blood Transfus Organ. 2010;7(1):17–56.
   Google Scholar
• Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S, et al. editors. Factor XIII deficiency in Iran: a comprehensive review of the literature. Seminars in thrombosis and hemostasis. 2015;41(3):323–9.
   Google Scholar
• Ghaffarpoor M, Sharifian R, Mehrabi F, Salehi M. Neurologic complications in hemophilia: a study in 214 cases. Acta Medica Iranica. 2001;39(4):182–4.
   Google Scholar
• Roushan N, Meysamie A, Managhchi M, Esmaili J, Dormohammadi T. Bone mineral density in hemophilia patients. Indian J Hematol Blood Transfus. 2014;30(4):351–5. doi: 10.1007/s12288-013-0318-4
   PubMed Web of Science ®Google Scholar
• Srivastava A, You SK, Ayob Y, Chuansumrit A, de Bosch N, Perez Bianco R, et al. editors. Hemophilia treatment in developing countries: products and protocols. Seminars in thrombosis and hemostasis. 2005: New York: Stratton Intercontinental Medical Book Corporation, c1974-.
   Google Scholar
• Kiadaliri AA, Pourmohammadi K, Bastani P, Karimi M. The impact of factor VIII inhibitors on factor consumption in haemophilia A: a case-control study in South of Iran. Middle East J Sc Res. 2011;8(3):694–8.
   Google Scholar
• Report on the WFH Global Survey. Compiled and produced by the World Federation of Hemophilia; 2010.
   Google Scholar
• Salimi C. The history of care in Iran, Hemophilia Today, Spring 2002, p. 13.
   Google Scholar
• Report on the WFH Global Survey. Compiled and produced by the World Federation of Hemophilia. 2005.
   Google Scholar
• Rasekh HR, Imani A, Karimi M, Golestani M. Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran. Clinicoecon Outcomes Res. 2011;3(2):207–12. doi: 10.2147/CEOR.S25909
   PubMedGoogle Scholar
• Daliri AAK, Haghparast H, Mamikhani J. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran. Int J Technol Assess Health Care. 2009;25(04):584–7. doi: 10.1017/S0266462309990420
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Brackmann H-H, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica. 2000;85(10 Suppl.):7–13. discussion 4.
   PubMedGoogle Scholar
• Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, et al. A Comparison of efficacy between recombinant activated factor VII (Aryoseven) and Novoseven in patients with Hereditary FVIII deficiency with inhibitor. Clin Appl Thromb Hemost. 2014;6(3):14–19.
   Google Scholar
• Nesheli HM, Hadizadeh A, Bijani A. Evaluation of inhibitor antibody in hemophiliaA population. Caspian J Intern Med. 2013;4(3):727.
   PubMedGoogle Scholar
• Torghabeh HM, Pourfathollah A, Shoosshtari MM, Rezaieyazdi Z. Coagulation therapy in hemophilia A and its relation to factor VIII inhibitor in Northeast of Iran. IJMS. 2004;29(4).
   Google Scholar
• Mansouri Torghabeh H, Pourfathollah A, Mahmoudian Shoushtari M. Evaluation of the relationship between factor IX inhibitor in hemophilia B patients and different types of therapy in the north-eastern part of Iran. Iran J Blood Cancer. 2009;1(2):83–6.
   Google Scholar
• Cheraghali AM, Eshghi P. Cost assessment of implementation of immune tolerance induction in Iran. Value Health Reg Issues. 2012;1(1):54–8. doi: 10.1016/j.vhri.2012.03.014
   PubMedGoogle Scholar
• Merat S, Rezvan H, Nouraie M, Jamali J, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med. 2009;12(3):225–31.
   PubMed Web of Science ®Google Scholar
• Owrang Eilami M, Sharifi A, Marzieh Tabatabaee M. High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad province, Southwest Iran. Arch Iran Med. 2012;15(5):271–4.
   PubMed Web of Science ®Google Scholar
• Javadzadeh-Shahshahani H, Attar M, Yavari M, Savabieh S. Study of the prevalence of hepatitis B, C and HIV infection in hemophilia and Thalassemia population of Yazd. Sci J Iran Blood Transfus Organiz Res Center. 2005;2(7):315–22.
   Google Scholar
• Abdollahi A, Shahsiah R, Nassiri Toosi M, Lak M, Karimi K, Managhchi M, et al. Seroprevalence of Human immunodificiency virus (HIV) and Hepatitis C infection in hemophilic patients in Iran. Iran J Pathol. 2008;3(3):119–24.
   Google Scholar
• Alavian S-M. Control of hepatitis C in Iran: vision and missions. Hepat Mon. 2007;7(2):57–8.
   Web of Science ®Google Scholar
• Javadzadeh SH, Attar M, Yavari MT, Savabieh S. Study of the prevalence of Hepatitis B, C and HIV infection in hemophilia and Thalassemia population of Yazd. Sci J Blood Transfus Organ. 2006;2(7):315–22.
   Google Scholar
• Moghaddam MA, Zali MR, Andabili SHA, Derakhshan F, Miri SM, Alavian SM. High rate of virological response to Peginterferon α-2a–Ribavirin among non-cirrhotic Iranian hemophilia patients with chronic Hepatitis C. Iran Red Crescent Med J. 2012;14(8):466–73.
   PubMed Web of Science ®Google Scholar
• Rafiei A, Darzyani AM, Taheri S, Haghshenas M, Hosseinian A, Makhlough A. Genetic diversity of HCV among various high risk populations (IDAs, thalassemia, hemophilia, HD patients) in Iran. Asian Pac J Trop Med. 2013;6(7):556–60. doi: 10.1016/S1995-7645(13)60096-6
   PubMed Web of Science ®Google Scholar
• Rahmani M, Toosi M, Ghannadi K, Lari G, Jazebi M, Rasoulzadegan M, et al. Clinical outcome of interferon and ribavirin combination treatment in hepatitis C virus infected patients with congenital bleeding disorders in Iran. Haemophilia. 2009;15(5):1097–103. doi: 10.1111/j.1365-2516.2009.02042.x
   PubMed Web of Science ®Google Scholar
• Yazdani MR, Kassaian N, Ataei B, Nokhodian Z, Adibi P. Hepatitis C virus infection in patients with hemophilia in Isfahan, Iran. Int J Prev Med. 2012;3(Suppl 1):S89–89.
   PubMedGoogle Scholar
• Alavian S, Ardeshir A, Hajarizadeh B. Seroprevalence of anti-HCV among Iranian hemophilia patients, Transfusion Today-Groningen, 2001;4(9):4–5.
   Google Scholar
• Mousavian S, Mansouri F, Saraei A, Sadeghei A, Merat S. Seroprevalence of hepatitis C in hemophilia patients refering to Iran Hemophilia Society Center in Tehran. Govaresh. 2011;16(3):169–74.
   Google Scholar
• Mansour-Ghanaei F, Fallah M-S, Shafaghi A, Yousefi-Mashhoor M, Ramezani N, Farzaneh F, et al. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (Northern Province of Iran). Med Sci Monit. 2002;8(12):CR797–CR800.
   PubMedGoogle Scholar
• Sharifi-Mood B, Sanei-Moghaddam S, Salehi M, Eshghi P, Khosravi S, Khalili M. Viral infection among patients with hemophilia in the Southeast of Iran. J Med Sci. 2006;6(2):225–8. doi: 10.3923/jms.2006.225.228
   Google Scholar
• Zahedi MJ, Darvishmoghadam S. Frequency of Hepatitis B and C infection among hemophiliac patients in Kerman. J Kerman Univ Med Sci. 2004;11(3):131–5.
   Google Scholar
• Assarehzadegan MA, Boroujerdnia MG, Zandian K. Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in ahvaz, southwest iran. Iran Red Crescent Med J. 2012;14(8):470–4.
   PubMed Web of Science ®Google Scholar
• Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol. 2005;80(1):55–63. doi: 10.1002/ajh.20390
   PubMed Web of Science ®Google Scholar
• Lak M, Sharifian RA, Karimi K, Mansouritorghabeh H. Acquired hemophilia A: clinical features, surgery and treatment of 34 cases, and experience of using recombinant factor VIIa. Clin Appl Thromb Hemost. 2009;3(4):48–53.
   Google Scholar
• Borna S, Hantoushzadeh S. Acquired hemophilia as a cause of primary postpartum hemorrhage. Arch Iran Med. 2007;10(1):107–10.
   PubMed Web of Science ®Google Scholar